Adjuvants

  • 1 BP-VLP Technology

    Nanovax Co., Ltd is developing a next-generation vaccine platform using Virus-Like Particle (VLP) technology derived from bacteriophages (BP).

    The BP-VLP platform offers superior safety and efficiency compared to conventional vaccines. It also enables the presentation of diverse antigens, making it an optimized solution for the prevention and treatment of infectious diseases.

    Advantages of Bacterial host.

    High expression level in E.coli

    High solubilized antigen

    Simple single coat protein.

    Convenient Multiple Antigen Present.

    Stable VLP formation

    Non-pathogenic to mammalian host

    BP-VLP

  • 2 Key Advantages of BP-VLP Technology

    Stable Bacteriophage-Based Expression System - Enables large-scale expression and production using bacterial hosts

    High Antigen Expression in E. coli - Enhances productivity and cost-efficiency in vaccine development

    Highly Solubilized Antigen - Minimizes protein aggregation and optimizes immune response

    Simple Single Coat Protein Structure - Forms stable VLPs without complex assembly processes

    Convenient Multiple Antigen Presentation - Capable of targeting multiple pathogens simultaneously

    Stable VLP Formation - Maintains vaccine efficacy and supports long-term storage

    Non-Pathogenic to Mammalian Hosts - Provides a safe platform for human and animal applications

    BP-VLP

    Antigen

    Antigen-VLP conjugate

    Applications of BP-VLP Technology

  • 3 Application Areas of BP-VLP Technology

    Development of Immune Adjuvants that Stimulate T-cell/B-cell Responses

    Vaccine Development Using Immunogenic Epitopes/Subunit Antigens

    Development of Targeted Delivery Systems for Specific Antigens

    Application Areas of Nanovax’s BP-VLP Technology

    Nanovax Co., Ltd is developing a next-generation vaccine platform using Virus-Like Particle (VLP) technology derived from bacteriophages (BP).

    The BP-VLP platform offers superior safety and efficiency compared to conventional vaccines. It also enables the presentation of diverse antigens, making it an optimized solution for the prevention and treatment of infectious diseases.

  • BP-VLP-Based Immune Adjuvant Development and Commercialization Plan

  • 1 What is Ferritin?

    A protein that stores and releases iron (Fe), an essential trace mineral in the body.

    Forms stable nanoparticles through self-assembly.

    Using recombinant technology, it is possible to fuse various antigens, compounds, etc., onto the particle surface, enabling applications in vaccine, drug delivery, and immune enhancer development.

  • 2 Nanovax’s Ferritin-Based System

    Nanovax Co., Ltd. is developing a next-generation biotechnology platform using ferritin's self-assembly properties for applications in vaccines, immune adjuvants, and drug delivery


    Adjuvant

    Drug Delivery System

    Fenobody Platform

    Vaccine